Apimeds Pharmaceuticals U... (APUS)
NYSE: APUS
· Real-Time Price · USD
1.84
0.09 (5.14%)
At close: Aug 19, 2025, 3:59 PM
1.89
2.72%
Pre-market: Aug 20, 2025, 08:26 AM EDT
Company Description
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company was incorporated in 2020 and is based in Hopewell, New Jersey.
Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
Apimeds Pharmaceuticals US Inc
| Country | United States |
| IPO Date | May 9, 2025 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik C. Emerson |
Contact Details
Address: 2 East Broad Street Hopewell, New Jersey United States | |
| Website | https://www.apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001894525 |
| CUSIP Number | 03771D102 |
| ISIN Number | US03771D1028 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | Chief Executive Officer & Director |
| Mark Corrao CPA | Chief Financial Officer |
| Dr. Christopher M. H. Kim M.D. | Chief Medical Officer & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | NT 10-Q | Filing |
| Jul 16, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 4/A | [Amend] Filing |
| Jun 11, 2025 | 3/A | [Amend] Filing |
| Jun 05, 2025 | 8-K | Current Report |
| May 23, 2025 | S-8 | Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | 4 | Filing |